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Type 2 diabetes mellitus (T2DM) is a risk factor for Parkinson's disease (PD). Therefore, 
treatment to improve insulin resistance in T2DM may be useful for PD patients. Glucose 
dependent insulinotropic polypeptide (GIP) is a member of the incretin hormone family that can 
promote insulin release and improve insulin resistance. Several GIP analogues have been 
developed as potential treatments for T2DM. We had shown previously that D-Ala2-GIP-glu-PAL, 
a novel long-acting GIP analogue, can play a neuroprotective role in the PD mouse model induced 
by acute MPTP injection. The drug reduced damage to the dopaminergic neurons and increased 
CREB-mediated Bcl-2 expression to prevent apoptosis and reduced chronic inflammation in the 
brain. In the present study, we further tested the effects of chronic treatment by 
D-Ala2-GIP-glu-PAL in a chronic PD mouse model induced by MPTP (25 mg/kg ip.) 
combination with probenecid (250 mg/kg ip.) injection for 5 weeks. The results demonstrated that 
chronic treatment with D-Ala2-GIP-glu-PAL inhibits MPTP -induced Parkinsonism-like motor 
disorders in mice, and that the drug prevents dopaminergic neuronal loss in the substantia nigra 
pars compacta (SNpc). Moreover, D-Ala2-GIP-glu-PAL also inhibited the increased levels of 
expression of α-synuclein in the SNpc and striatum induced by MPTP. Furthermore, drug 
treatment reduced chronic neuroinflammation, oxidative stress and lipid peroxidation, and 
increased the expression of BDNF. These findings show that GIP signaling is neuroprotective and 
holds promise as a novel treatment of PD.   
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1. Introduction  
 
Parkinson's disease (PD) is a degenerative neurological disorder affecting over 1% of the 
population. A key aspect of the disease is the progressive loss of dopaminergic neurons in the 
substantia nigra pars compacta (SNpc), and in some cases, the aggregation of α-synuclein in 
neurons (Kowal et al., 2013). Disease- modifying treatments for PD are still lacking. Similarities 
between PD and Type 2 diabetes mellitus (T2DM) have been discovered recently. A clinical data 
meta-analysis found that 8-30 % of PD patients were diabetic, a significantly higher percentage 
compared to age matched controls (Cereda et al., 2011; Hu et al., 2007; Miyake et al., 2010). A 
histological study found a loss of insulin receptor immunoreactivity in the SNpc neurons in PD, 
and a dysfunction of the insulin signaling system may precede death of the dopaminergic neurons 
(Moroo et al., 1994). Also, exendin-4, an agonist for the glucagon-like peptide-1 receptor 
(GLP-1R) that is on the market to treat T2DM, showed therapeutic effects in preclinical tests 
(Kim et al., 2009; Li et al., 2009). Furthermore, a pilot clinical trial in PD patients showed good 
effects with this drug (Aviles-Olmos et al., 2013; Foltynie and Aviles-Olmos, 2014; Simuni and 
Brundin, 2014). Hence, a treatment to improve insulin resistance may be useful for PD patients 
(Athauda and Foltynie, 2016).  
Glucose-dependent insulinotropic polypeptide (GIP) is a member of the incretin hormone family 
(Baggio and Drucker, 2007). Several protease-resistant GIP analogues have been developed as 
potential treatments for type 2 diabetes (Irwin et al., 2006). In the central nervous system, GIP and 
the GIPR is found in the hippocampus, cerebellum, cerebral cortex, substantia nigra, thalamus, 
the hypothalamus, and the brainstem (Nyberg et al., 2005; Nyberg et al., 2007). GIP modulates 
synaptic activity – D-Ala2GIP prevented the detrimental effects of Aβ on synaptic plasticity in the 
hippocampus (Gault and Holscher, 2008) and on spatial learning and memory (Figueiredo et al., 
2011). In our previous studies, chronic injection of D-Ala2GIP enhanced memory formation, 
long-term potentiation (LTP) in the hippocampus, and progenitor cell proliferation in the dentate 
gyrus of mice (Faivre et al., 2012; Porter et al., 2011). Moreover, D-Ala2GIP improved cognitive 
function and prevented memory deficits in the APP/PS1 mouse model of Alzheimer’s disease, and 
reduced the Aβ plaque load and chronic inflammation in the brain (Duffy and Holscher, 2013; 
Faivre and Holscher, 2013a, b). 
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Based on this information, we previously have tested the effects of a novel GIP analogue, 
D-Ala2-GIP-glu-PAL in a PD mouse model induced by acute MPTP injection without added 
probenecid. The results demonstrated that treatment with D-Ala2-GIP-glu-PAL significantly 
inhibited MPTP-induced Parkinsonism-like motor impairments in mice, and reduced damage to 
dopaminergic neurons. Moreover, the drug increased CREB-mediated Bcl-2 expression to prevent 
apoptosis and reduced chronic neuroinflammation (Li et al., 2016). To further analyse the 
underlying molecular mechanisms, we studied the effects of systemic administration of 
D-Ala2-GIP-glu-PAL in a chronic mouse model of PD induced by MPTP in combination with 
probenecid treatment which enhances the toxic MPTP effect (Korecka et al., 2013; Meredith et al., 
2008). Chronic lesion with MPTP is a more realistic model of the progressive neurodegenerative 
development in PD.  
 
 
2. Material and methods 
 
2.1 Reagents and peptides 
Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and probenecid were purchased from 
Sigma-Aldrich (St Louis, MO, USA). RIPA lysis buffer, BCA protein assay kit and 
ECL-enhanced chemoluminescence were purchased from Beyotime Institute of Biotechnology 
(Shanghai, China). The primary antibodies recognising TH, IBA1, 4-Hydroxynonenal (4-HNE), 
BDNF and β-actin were obtained from Abcam (Cambridge, UK). The primary antibody against 
α-synuclein was obtained from Cell Signaling Biotechnology (Beverly, MA, USA) and the 
primary antibody against GFAP was obtained from Boster Biotechnology (Wuhan, China). 
HRP-labeled goat anti-rabbit immunoglobulin was obtained from Abcam (Cambridge, UK). The 
biotinylated goat anti-rabbit IgG, biotinylated rabbit anti-goat IgG, avidin-biotin peroxidase 
complex reagent was purchased from Boster Biotechnology (Wuhan, China). The 3, 
3-diaminobenzidine (DAB) solution was obtained from Zhongshan Golden Bridge Biotechnology 
(Beijing, China). All other chemicals used were of analytical grade and of the highest quality 
commercially available.  
D-Ala2-GIP-glu-PAL was synthesized by GL Biochem Ltd (Shanghai). The purity of the peptide 
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was analysed by reversed-phase high performance liquid chromatography (HPLC) and 
characterised using matrix-assisted laser desorption/ionisation time of flight (MALDI-TOF) mass 




(PAL = C16 fatty acid) 
 
2.2 Animals and drug treatments  
Adult male C57BL/6 mice (25–30 g) were purchased from the Academy of Military Medical 
Sciences (AMMS, China). The animals were maintained on 12-h light/dark cycle at 24 ℃ ± 1℃ 
and 55 ± 5% humidity with food and water ad libitum, and were acclimatized for at least 1 week 
prior to the medication. All experimental procedures involving animals in the present study were 
approved by the Institutional Animal Care Committee of Shanxi Medical University and conform 
to the guidelines of National Institute of Health (NIH) guideline (NIH publication NO. 85-23. 
Revised 1985). 
Mice were divided into four different groups (n=12 per group) consisting of (i) a control group 
treated with saline alone; (ii) a group treated with D-Ala2-GIP-glu-PAL; (iii) a group treated with 
MPTP and probenecid; and (iv) a group treated with D-Ala2-GIP-glu-PAL in combination with 
MPTP and probenecid. Mice were intraperitoneally injected with 10 doses of MPTP (25 mg/kg in 
saline) and probenecid (250 mg/kg in dimethyl sulfoxide) for 5 weeks with an interval of 3.5 days 
between consecutive doses. D-Ala2-GIP-glu-PAL was dissolved in saline and drug (25nmol/kg 
body weight,) ip. was treated one time per day during MPTP and probenecid injection and 
continued for 1 week after MPTP and probenecid injection. Control mice received equal volumes 
of saline solution. At the end of drug treatments, measurements of behavioral changes, neuronal 
damage, and pathologic biomarkers were conducted.      
 
2.3 Behavioral assessment 
 
2.3.1 Open-field test  
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To assess locomotor and exploratory activity of mice, the open-field test was conducted on the 6
th
 
weeks as previously described (Li et al., 2016). The open-field apparatus consisted of a square 
arena (50 cm*50 *cm *40 cm) with a floor divided into 25 equal-sized squares with grids. Each 
mouse was placed in the center of the square arena and allowed to move freely for 5 min. Two 
parameters of mouse were measured in this experiment: the number of crossing line (crossing the 
squares boundaries with both forepaws) and the number of rearing (standing on its hind legs and 
sometimes leaning on the wall with forelegs, sniffing and looking around). The surface of the 
arena was then cleaned with 70% alcohol and dried between trials. The evaluation was conducted 
by an investigator who was unaware of the information of grouping and drug administration. The 
experiment was repeated 2 times for each animal, and the average of 2 trials was calculated for 
statistical analyses.  
  
2.3.2 Pole test 
To determine the degree of bradykinesia and ability to movement balance of mice, the pole test 
was conducted on the 6
th
 weeks as previously described (Li et al., 2016). In brief, animals were 
positioned head upward near the top of a rough-surfaced wooden pole (10 mm in diameter and 55 
cm in height). The time taken until animals turned around completely and face the floor 
downward (defined as turn time, T-turn) and the time taken to climb down the pole and place all 
four feet on the floor (locomotor activity time, T-LA) were recorded. If the mouse did not descend 
in 30s, it was guided, and T-turn was recorded as 30s. Before drug injections, all mice were 
pre-trained for pole test procedure for three times a day for five consecutive days. Every mouse 
was tested for 3 times and the average of the three trials was calculated for statistical analyses. 
The investigator was blind to the treatments given to mice.    
  
2.3.3 Rotarod test 
To determine the degree of hypokinesia and motor coordination of mice, the rotarod test was 
conducted on the 6
th
 weeks as previously described (Liu et al., 2015). The rotarod equipment 
(YLS-4C, Academy of medical sciences in Shandong, China) consisted of a rotating spindle (3 
cm in diameter) and five individual compartments able to simultaneously test five mice. Before 
initiation of the experiment, all mice were trained on rotarod for three times a day for five 
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consecutive days. On the 6th weeks of experiment, mice were placed on a rod that accelerated 
smoothly from 5 to 20 rpm over a period of 180s. The time that each mouse was able to stay on 
the rod was recorded as the latency period to fall. The experiment was repeated 3 times for each 
mouse at 10 min rest intervals to prevent stress and fatigue. The average of the three trials was 
calculated for statistical analyses. The investigator was blind to the treatments given to mice.   
 
2.4 Sample preparation 
All animals were killed on the end of the 6
th
 weeks. After anesthetization with ethyl carbamate, 
whole brains of half of mice per group were removed immediately and ventral midbrain was 
dissected out and stored at −80 °C for western blot analysis. And another half of mice per group 
were transcardial perfused with ice-cold PBS and 4% paraformaldehyde/PBS (pH7.4), and brains 
were removed and post-ﬁxed for 24 h in the same ﬁxative, and the brains were embedded in 
paraffin.  
 
2.5 Immunohistochemistry   
The sections of brain tissue samples were cut at 4 μm with a microtome. The sections 
encompassing the SNpc and the striatum were placed on coated slides. Paraffin was removed 
from the tissue sections with xylene, and the sections were rehydrated in graded ethanol solutions. 
Endogenous peroxidase activity was blocked with 3% H2O2 for 5 min. Antigen retrieval was 
performed by heating in 10 mmol/l citrate buffer (pH 6.0) for 10 min. After blocked with 5% BSA, 
sections were incubated with the primary antibody for TH (rabbit anti-TH; 1:500), GFAP (rabbit 
anti-GFAP; 1:100), IBA1 (goat anti-IBA1; 1:500), α-synuclein (rabbit anti-α-synuclein; 1:200) 
and 4-HNE (rabbit anti- 4-HNE; 1:200) at 37℃ for 1h. After rinsed in PBS, the sections were 
incubated with biotinylated goat anti-rabbit IgG or biotinylated rabbit anti-goat IgG at 37℃ for 
0.5h and incubated with followed by the avidin-biotin peroxidase complex reagent at 37℃ for 
0.5h. Samples were colored in 3,3-diaminobenzidine (DAB) solution in the presence of H2O2. To 
verify the immune specificity, control sections were processed with the same protocol, except that 
omitting the primary antibody. And some sections were retained used with hematoxylin. All 
stained sections were viewed and photographed under a Zeiss light microscope, and images were 
captured by digital camera (Motic BA210).   
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Quantitative analysis of DA neurons in SNpc was carried out by serial section analysis of the total 
number of TH positive (TH+) neurons throughout the rostro-caudal axis. Only the region 
corresponding to the SNpc was carefully delineated, according to the mouse brain atlas of Paxinos 
(Paxinos et al., 1999). Using the method of unbiased 2D stereology, a dissector was overlaid onto 
the micrographs of the brain section. The ratio percent of the total number of TH+ neurons of 
every mouse and average TH+ neurons of control group was calculated for statistical analyses. 
The optical density of dopaminergic neuron termini in the striatum were determined from scanned 
TH+ sections by digital densitometry using Image-pro plus6.0 software. The areas of GFAP and 
IBA1 positive cells, the average optical density of α-synuclein and 4-HNE positive staining in the 
SNpc and striatum were also determined using Image-pro plus6.0 software.     
 
2.6 Western blot   
Western blot assay was performed using standard protocols. Midbrain tissues containing 
substantia nigra were homogenized on ice in RIPA lysis buffer containing phenyl-methylsulfonyl 
fluoride (PMSF). After 30 min, tissue lysates were obtained by centrifugation at 12000 rpm 
(28000 G) for 5 min at 4°C. The protein concentration of the samples then was quantified by BCA 
protein assay. After tissue lysate was mixed in loading buffer and boiled for 5 min, equivalent 
amounts of protein were separated on 12% SDS-polyacrylamide gel and transferred to 
polyvinylidene difluoride (PVDF) membranes. The membranes were blocked with 5% milk in 
Tris-buffered saline and incubated overnight at 4°C with rabbit anti-mouse α-synuclein(1:1000,) 
and anti-mouse BDNF(1:5000), followed by incubation for 2h at room temperature with the 
HRP-labeled goat anti-rabbit immunoglobulin (1:10000). The bound antibodies were then 
visulalized by ECL-enhanced chemoluminescence according to the manufacturer’s instructions. 
In some cases, the blots were stripped and reprobed with a rabbit anti-mouse β-actin (1:5000) to 
ensure equal sample loading. Western blot images were captured with a chemiluminescent 
imaging system (Sagecreation, Beijing, China). All bands were quantified using the image system 
of Quantity one 4.31(Bio-Rad, Hercules, CA, USA). 
 
2.7 Statistical analysis 
All data are presented as the mean ±standard error of mean (SEM). Statistical assessment was 
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analyzed by one way analysis of variance (ANOVA) followed with post-hoc Bonferroni tests 
between four different groups. A value of P < 0.05 was considered statistically significant. All 
analyses were performed with the Graph Pad Prism version 5.0 Software (GraphPad Software Inc, 
La Jolla, CA, USA). 
 
3. Results  
  
3.1 D-Ala2-GIP-glu-PAL alleviated motor impairments induced by MPTP and probenecid 
In the open field test, D-Ala2-GIP-glu-PAL alleviated the impairments of locomotor and 
exploratory activity of mice induced by MPTP and probenecid. A one-way ANOVA found an 
overall difference on the numbers of crossings (F=9.83, df=11; P<0.001) and the numbers of 
rearing (F=17.87, df=11; P<0.001) of mice between groups. In post-hoc Bonferroni tests, the 
results showed that the numbers of crossings in MPTP and probenecid group mice exhibited a 
significant reduction versus the control group mice (P<0.01). However, D-Ala2-GIP-glu-PAL 
treatment reversed these effects on crossing (P<0.05). Furthermore, MPTP and probenecid 
procedure also decreased the numbers of rearing (P<0.001), and D-Ala2-GIP-glu-PAL could 
improve the numbers of rearing (P<0.05). Although numbers of crossings and rearing in MPTP 
and probenecid + D-Ala2-GIP-glu-PAL group mice were still less than control group, there was 
no significant(P>0.05). N =12 mice in each group, see Fig. 1A.  
In the pole test, D-Ala2-GIP-glu-PAL improved the bradykinesia and movement imbalance of 
mice induced by MPTP and probenecid. A one-way ANOVA found an overall difference on T-turn 
(F= 19.78, df=11; P<0.001) and T-LA (F=10.66, df=11; P<0.001) of mice between groups. In 
post-hoc Bonferroni tests, the results showed that MPTP and probenecid injection induced the 
bradykinesia of mice, with more time to turn at the top (T-turn) (P<0.001) compared with the 
control. The MPTP and probenecid injection also induced movement imbalance of mice, with 
more time required by mice to climb down (T-LA) (P<0.001) compared to controls. However, 
treatment with D-Ala2-GIP-glu-PAL significantly reversed these effects induced by MPTP and 
probenecid (P<0.05). But T-turn in MPTP and probenecid + D-Ala2-GIP-glu-PAL group mice 
were still more than control group(P<0.01). Although T-LA in MPTP and probenecid + 
D-Ala2-GIP-glu-PAL group mice were still more than control group, there was no 
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significant(P>0.05).N =12 mice in each group, see Fig. 1B. 
In the rotarod test, D-Ala2-GIP-glu-PAL improved muscular strength and hypokinesia of mice 
induced by MPTP and probenecid. A one-way ANOVA found an overall difference between 
groups (F=16.97, df=11; P<0.001). In post-hoc Bonferroni tests, the results showed that MPTP 
and probenecid injection induced the impairments in muscular strength and movement balance of 
mice, with less time staying on the rotating rod (drop latency) (P<0.001) compared with the 
control. However, treatment with D-Ala2-GIP-glu-PAL significantly reversed these effects 
induced by MPTP and probenecid (P<0.05). But drop latency in MPTP and probenecid + 
D-Ala2-GIP-glu-PAL group mice were still less than control group(P<0.05). N =12 mice in each 
group, see Fig. 1C. 
 
3.2 D-Ala2-GIP-glu-PAL reduced dopaminergic neuronal loss induced by MPTP and 
probenecid  
The expression of tyrosine hydroxylase (TH), a key enzyme for the synthesis of dopamine, was 
analyzed by immunohistochemical staining which identifies dopaminergic neurons. A one-way 
ANOVA found an overall difference on the numbers of TH positive cells in the SNpc (F= 36.70, 
df=5; P<0.001) and the striatum (F= 30.54, df=5; P<0.001) of mice between groups. There is no 
difference between control group and D-Ala2-GIP-glu-PAL group. The numbers of TH positive 
cells in the SNpc was decreased to 33.99% of control group (P<0.001), and the average optical 
density of TH staining in the striatum was decreased to 56.75% of control group (P<0.001) by 
MPTP and probenecid injection for 5 weeks. However, D-Ala2-GIP-glu-PAL treatment restored 
numbers of dopaminergic neurons to 59.21% in SNpc (P<0.05) and the overall levels of TH to 
73.33% in the striatum (P<0.05) in MPTP and probenecid -treated mice. But the numbers of TH 
positive cells in the SNpc and the average optical density of TH staining in the striatum in MPTP 
and probenecid + D-Ala2-GIP-glu-PAL group mice were still less than control group(P<0.001). N 
=6 mice in each group, see Fig. 2. 
 
3.3 D-Ala2-GIP-glu-PAL inhibited the increase of α-synuclein expression in the SNpc and 
striatum induced by MPTP and probenecid 
The level of α-synuclein, a primary structural component of Lewy body, was analyzed by Western 
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blot and immunohistochemical staining. 
In the Western blot, a one-way ANOVA found an overall difference between groups (F=11.49, 
df=5; P<0.001). The expression of α-synuclein in SNpc was increased in mice treated with MPTP 
and probenecid (P<0.001), compared to control. While D-Ala2-GIP-glu-PAL treatment partially 
reversed the increase (P <0.05) compared to the MPTP and probenecid group. Although the 
expression of α-synuclein in SNpc in MPTP and probenecid + D-Ala2-GIP-glu-PAL group mice 
were still higher than control group, there was no significant(P>0.05).N =6 mice in each group, 
see Fig. 3. 
In the immunohistochemical staining, a one-way ANOVA found an overall difference on the 
α-synuclein expression in the SNpc (F=37.32, P<0.001) and the striatum(F=18.34, df=5; P<0.001) 
of mice between groups. The expression of α-synuclein in the SNpc and striatum of control mice 
was moderate. There is no difference between control group and D-Ala2-GIP-glu-PAL group. The 
average optical density of α-synuclein positive staining in the SNpc and striatum was significantly 
increased by MPTP and probenecid injection for 5 weeks (P<0.001) compared with control mice. 
However, D-Ala2-GIP-glu-PAL treatment decreased the effects induced by MPTP and probenecid 
(P<0.05). But the average optical density of α-synuclein positive staining in the SNpc(P<0.001) 
and striatum(P<0.05) in MPTP and probenecid + D-Ala2-GIP-glu-PAL group mice were still 
higher than control group. N =6 mice in each group, see Fig. 3. 
 
3.4 D-Ala2-GIP-glu-PAL reduced astrocyte and microglia activation in the SNpc and 
striatum induced by MPTP and probenecid 
In the immunohistochemical analysis, an anti-GFAP antibody was used as an indicator of 
activated astrocytes. GFAP is expressed at a much higher rate in activated astrocytes and indicates 
an inflammation response. A one-way ANOVA found an overall difference on the GFAP 
expression in the SNpc (F= 121.7, df=5; P<0.001) and the striatum (F= 94.13, df=5; P<0.001) of 
mice between groups. GFAP-positive stain covered an average of 2.22% of each section in the 
SNpc of control mice, and covered an average of 0.85% of each section in the striatum. There was 
no difference between the control and the D-Ala2-GIP-glu-PAL injection group. GFAP levels in 
the SNpc increased to 14.83% after MPTP and probenecid treatment for 5 weeks, and in the 
striatum increased to 10.92%, which was significantly higher than in control mice (P<0.001). 
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While D-Ala2-GIP-glu-PAL treatment reduced the area of GFAP-positive stain in the SNpc to 
8.52%, in the striatum to 4.82%, which was significantly less than in the MPTP and probenecid 
procedure group (P<0.001). But the areas of GFAP-positive astrocytes in the SNpc and striatum 
in MPTP and probenecid + D-Ala2-GIP-glu-PAL group mice were still higher than control 
group(P<0.001). N =6 mice in each group, see Fig. 4. 
 
In the immunohistochemical staining of IBA1, which is expressed at a much higher rate in 
activated microglia, a one-way ANOVA found an overall difference on the IBA1 expression in the 
SNpc (F= 45.92, df=5; P<0.001) and the striatum (F= 43.24, df=5; P<0.001) of mice between 
groups. IBA1-positive stain covered an average of 0.21% of each section in the SNpc of control 
mice, and covered an average of 0.40% of each section in the striatum. There was no difference 
between control and the D-Ala2-GIP-glu-PAL injection group. IBA1 levels in the SNpc increased 
to 1.27% after MPTP and probenecid treatment for 5 weeks, and in the striatum increased to 
1.11%, which were significantly higher than in control mice (P<0.001). While 
D-Ala2-GIP-glu-PAL treatment decreased the areas of IBA1-positive microglia in SNpc to 0.58% 
and in the striatum to 0.79%, which was significantly less than in the MPTP and probenecid 
procedure group (P<0.01). But the areas of IBA1-positive microglia in the SNpc (P<0.01) and 
striatum (P<0.001) in MPTP and probenecid + D-Ala2-GIP-glu-PAL group mice were still higher 
than control group. N =6 mice in each group, see Fig. 5. 
 
3.5 D-Ala2-GIP-glu-PAL reduced lipid peroxidation in the SNpc and striatum induced by 
MPTP and probenecid 
In the immunohistochemical analysis, 4-HNE was measured as an indicator of lipid peroxidation. 
A one-way ANOVA found an overall difference on 4-HNE expression in the SNpc (F=13.76, df=5; 
P<0.001) and the striatum (F=10.25, df=5; P<0.001) of mice between groups. There is no 
difference between control group and the D-Ala2-GIP-glu-PAL group. The average optical 
density of 4-HNE staining in the SNpc and striatum was significantly increased by MPTP and 
probenecid injection for 5 weeks (P<0.001), compared with the control group. However, 
D-Ala2-GIP-glu-PAL treatment decreased the levels induced by MPTP and probenecid (P<0.001). 
Although the expression of 4-HNE in SNpc and striatum in MPTP and probenecid + 
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D-Ala2-GIP-glu-PAL group mice were still higher than control group, there was no 
significant(P>0.05).N =6 mice in each group, see Fig. 6.  
  
3.6 D-Ala2-GIP-glu-PAL inhibited the decrease of BDNF expression in the SNpc induced by 
MPTP and probenecid 
The expression of BDNF, an important neurotrophic factor in the brain, was analyzed by Western 
blot. A one-way ANOVA found an overall difference between groups (F=15.39, df=5; P<001). 
The expression of BDNF in SNpc was much decreased in mice treated with MPTP and 
probenecid (P<0.001), compared to control. While D-Ala2-GIP-glu-PAL treatment partially 
reversed the decrease (P <0.05) compared to the MPTP and probenecid group. Although the 
expression of BDNF in SNpc in MPTP and probenecid + D-Ala2-GIP-glu-PAL group mice were 
still less than control group, there was no significant(P>0.05).N =6 mice in each group, see Fig. 7. 
 
4. Discussion  
 
In the present study, we showed antiparkinsonian effects of chronic systemic administration of 
D-Ala2-GIP-glu-PAL in a chronic mouse model of PD induced by MPTP in combination with 
probenecid. The neurotoxin MPTP has been shown to induce Parkinsonism in humans 
(Przedborski and Jackson-Lewis, 1998), and is widely used for modeling Parkinsonism in rodents 
and non-human primates (Fox and Brotchie, 2010). The chemical MPTP can cross the 
blood–brain barrier and is converted in the cell to 1-methyl-4-phenylpyridium ion (MPP+) by the 
monoamine oxidase B in glia and dopaminergic neurons (Glover et al., 1986). MPP+ is 
selectively transported into neurons by the dopamine transporter. In the cell it inhibits the 
mitochondria complex I which induces oxidative stress and exerts cytotoxic effects on 
dopaminergic neurons (Gerlach et al., 1991). Probenecid is known to promote MPTP/MPP+ build 
-up in the brain and potentiates its neurotoxic effect by impeding the renal excretion and neuronal 
clearance of MPTP and its toxic metabolites. As animals do not naturally develop PD, the MPTP 
and probenecid chronic lesion mouse model is used to test new drug candidates for their 
Neuroprotective properties (Meredith et al., 2008). 
In the present study, the behavioral assessment demonstrated that D-Ala2-GIP-glu-PAL 
 14 
significantly alleviates motor disorders induced by MPTP and probenecid. This finding was 
consistent with the results of our previous study (Li et al., 2016). As TH is a key enzyme in the 
dopamine synthesis, the changes in TH levels indicate a reduction in the synthesis of dopamine in 
SNpc neurons. Following lesion with MPTP and probenecid for 5 weeks, TH positive neuron 
numbers in SNpc were reduced to 33.99% of controls, and TH levels in the striatum was 
decreased to 56.75%. However, D-Ala2-GIP-glu-PAL treatment for 6 weeks restored numbers of 
dopaminergic neurons to 59.21% in SNpc and the overall levels of TH to 73.33% in the striatum. 
A similar protection of neurons by GIP analogues was observed in a mouse model of AD (Faivre 
and Holscher, 2013a, b; Gault and Holscher, 2008). GIP treatment also showed neuroprotective 
effects in a rat model of traumatic brain injury by reversing cognitive impairments and reducing 
the chronic inflammation response in the brain (Yu et al., 2016).   
Besides progressive loss of dopaminergic neurons in the SNpc, the formation of Lewy Bodies 
(LB), which are cytoplasmic inclusions mainly containing α-synuclein, are among the 
pathological hallmarks of PD (Yasuda et al., 2013). In the present study, the expression of 
α-synuclein was analyzed by Western blot and immunohistochemistry. The results showed that 
α-synuclein expression in SNpc and striatum was increased following treatment with MPTP and 
probenecid, which confirms previous studies in which α-synuclein was up-regulated in 
MPTP-treated animals (Kuhn et al., 2003) and α-synuclein-positive neurons that were also 
TH-positive (Vila et al., 2000). Transgenic α-synuclein overexpressing mice develop deficits in 
motor function at 12 weeks when the loss of DA neurons exceeds a threshold of around 50%. The 
overexpression of α-synuclein induced progressive nigrostriatal degeneration and increased the 
susceptibility of DA neurons to MPTP (Song et al., 2015). The results of immunohistochemistry 
showed that in normal mice, detectable levels of α-synuclein protein were seen in all brain regions 
studied and especially in the ventral midbrain. In the latter, there was a dense α-synuclein-positive 
nerve fiber network in the SNpc, and only few scattered α-synuclein-positive neurons. After 
MPTP and probenecid treatment, numbers of α-synuclein-positive neurons were increased in the 
SNpc and there was an increase of α-synuclein levels in some neurons. However, 
D-Ala2-GIP-glu-PAL significantly inhibited the increase of α-synuclein expression, by which 
D-Ala2-GIP-glu-PAL may reduce the α-synuclein-related pathological mechanism of PD.   
Chronic inflammation is thought to play a central role in PD pathogenesis (Ferrari and Tarelli, 
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2011). In clinical studies, high concentrations of pro-inflammatory cytokines such as interleukin 
(IL)-1b, IL-6, and tumor necrosis factor (TNF)-α have been found in the brain, cerebrospinal fluid, 
and blood of PD patients (Chen et al., 2008). Abnormal production of pro-inflammatory cytokines 
by activated microglia and astrocytes can lead to synapse dysfunction and ultimately synapse loss 
(Herrero et al., 2015). Co-culture of activated astrocytes with primary dopaminergic cultures leads 
to increased susceptibility of dopaminergic neurons to MPP+ and 6-OHDA -mediated cell death 
(McNaught and Jenner, 1999). Hence, anti-inflammatory medication is an attractive therapeutic 
strategy for PD (Hirohata et al., 2008). In the present study, a chronic inflammation response in 
the SNpc and striatum of mice was indicated by the increased levels of GFAP in astrocytes and 
IBA1 in microglia after MPTP and probenecid treatment. Importantly, the chronic inflammation 
response was reduced by D-Ala2-GIP-glu-PAL treatment. We previously have reported that 
another GIP analogue, D-Ala2-GIP, also decreased neuroinflammation in the cortex of APP/PS1 
mice (Duffy and Holscher, 2013). In an acute PD model, we previously demonstrated that 
D-Ala2-GIP-glu-PAL also inhibited neuroinflammation in the SNpc induced by MPTP short-term 
injection (Li et al., 2016). Growth factors in general have anti-inflammatory properties which is 
an important part of their cytoprotective and regenerative effects (Cotman et al., 2007). Therefore, 
the reduction of the inflammation response may be one of the mechanisms by which GIP 
analogues inhibit the pathogenesis of neurodegenerative diseases.   
There is growing evidence that oxidative stress and following lipid peroxidation contribute the 
pathogenesis of PD (Andersen, 2004). 4-HNE is one of the markers of membrane lipid 
peroxidation induced by cytotoxic radicals such as •OH. 4-HNE has cytotoxic, mutagenic and 
genotoxic properties and 4-HNE is reported to stimulate apoptosis via caspase 3 activation and 
mitochondrial damage as shown in cytochrome c release (Ji et al., 2001). In PD, lipid 
peroxidation and the level of 4-HNE in SNpc are increased (Andersen, 2004; Dexter et al., 1989). 
Moreover, conjugates of 4-HNE and α-synuclein have been reported to increase protein 
misfolding and impair degradation, resulting in its buildup in the neuron (Friguet and Szweda, 
1997; Okada et al., 1999). In our present study, the levels of 4-HNE in the SNpc and striatum was 
significantly increased by MPTP and probenecid injection for 5 weeks, which was consistent with 
previous studies in which protein level of 4-HNE in midbrain was increased when MPTP was 
administered (Aras et al., 2014; Liang et al., 2007; Selley, 1998). However, D-Ala2-GIP-glu-PAL 
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treatment decreased the levels of 4-HNE of the regions studied. Hence, D-Ala2-GIP-glu-PAL 
reduces oxidant stress, which may promote cell survival of dopaminergic neuron in the SNpc 
when treated with MPTP and probenecid. However, whether these effects of GIP analogue arose 
from elevation of endogenous antioxidant substances cannot be resolved by the present data. As 
GIP itself is a trophic factor, it is possible to promote the production of endogenous antioxidant 
substance by activating the GIPR signal transduction pathway (Maino et al., 2014).  
BDNF is a member of the nerve growth factor (NGF) family in the brain. Clinical data have 
demonstrated that DA neurons which survive in the substantia nigra of PD brains express low 
levels of BDNF mRNA with significantly low levels of BDNF protein (Chauhan et al., 2001; 
Howells et al., 2000). Inhibiting BDNF expression by antisense oligonucleotide infusion causes 
loss of nigral dopaminergic neurons (Porritt et al., 2005). In contrast, in a MPTP-induced 
parkinsonian primate model, intrathecal injection of BDNF has shown neuroprotective effects on 
DA neurons (Tsukahara et al., 1995). Treatment with BDNF increased the number of surviving 
dopaminergic neurons and promoted sprouting of dopaminergic axons in mesencephalic cultures 
(Hyman et al., 1991). Hence, reduced BDNF expression in the substantia nigra may contribute to 
the death of nigral dopaminergic neurons and the development of PD. In the present study, the 
expression of BDNF in SNpc was much decreased in mice treated with MPTP and probenecid 
compared to control. However, D-Ala2-GIP-glu-PAL treatment partially reversed the decrease of 
BDNF induced by MPTP. The findings are consistent with the results of our previous study, in 
which a novel dual GLP-1 and GIP receptor agonist increased the expression of BNDF in the 
brain (Ji et al., 2016).  
In the central nervous system, the expression of BNDF can be enhanced by CREB signaling 
activation (Zhen et al., 2016), and the neuroprotective effect of CREB/BDNF signaling is 
correlated with a decrease in oxidative load (Lee et al., 2009). GIP receptors activate an 
adenylyl-cyclase and enhance intracellular cAMP levels, which in turn activates Protein Kinase A 
(PKA), which phosphorylates the cAMP-response element binding protein (CREB) (Holscher, 
2014; Kim et al., 2008). The cAMP/PKA/CREB cell signaling cascade is most likely the pathway 
via which GIP enhances BDNF expression. It is a classic growth-factor cell signaling cascade and 
plays a regulatory role in the nervous system and promotes neuronal survival, precursor cell 
proliferation and synaptic activity (Hussain et al., 2006). In our previous study, 
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D-Ala2-GIP-glu-PAL treatment partially reversed the decrease of p-CREB
S133 
levels induced by 
the MPTP treatment. These findings demonstrated that D-Ala2-GIP-glu-PAL can facilitate CREB 
activation, enhance the expression of BDNF, and ultimately promote cell survival of 
dopaminergic neurons in the SNpc.   
In conclusion, long-acting GIP analogues show promise as novel treatments that not only improve 
the symptoms but prevent the neurodegenerative processes underlying PD. The combination of 
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Fig. 1. D-Ala2-GIP-glu-PAL alleviated motor symptoms of PD mice induced by MPTP and 
probenecid. A: The results of the open field test showed that D-Ala2-GIP-glu-PAL protects from 
the MPTP-induced impairment in motor activity and exploration of mice. B: The results of the 
pole test showed that D-Ala2-GIP-glu-PAL improves the bradykinesia and imbalance induced by 
MPTP and probenecid. C: The results of the rotarod test showed that D-Ala2-GIP-glu-PAL 
improves muscular strength and hypokinesia induced by MPTP and probenecid. The values 
represent the means±S.E.M.; **P<0.01, ***P<0.001 compared with the control group, 
#
P<0.05 
compared with the MPTP and probenecid group, n=12 per group.  
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Fig. 2. Top: D-Ala2-GIP-glu-PAL restored tyrosine hydroxylase (TH) positive dopaminergic 
neuron numbers in the SNpc. (A-D)-TH positive neuron numbers were reduced following 
treatment with MPTP and probenecid, and increased by D-Ala2-GIP-glu-PAL. A: Saline; B: 
D-Ala2-GIP-glu-PAL; C: MPTP + probenecid; D: MPTP + probenecid + D-Ala2-GIP-glu-PAL. 
Scale bar in image C: 200μm. Graph: D-Ala2-GIP-glu-PAL treatment restored numbers of 
dopaminergic neurons in the SNpc of mice treated with MPTP and probenecid. Bottom: 
D-Ala2-GIP-GLU-PAL restored TH expression in the striatum. (A-D)-TH positive nerve fibers 
were reduced following treatment with MPTP and probenecid, and increased by 
D-Ala2-GIP-glu-PAL. A: Saline; B: D-Ala2-GIP-glu-PAL; C: MPTP + probenecid; D: MPTP + 
probenecid + D-Ala2-GIP-glu-PAL. Scale bar in image C: 500μm. Graph: D-Ala2-GIP-glu-PAL 
treatment restored levels of TH staining in the striatum of mice treated with MPTP and 
probenecid. The values represent the means±S.E.M. ***P<0.001 compared with the control group. 
#




Fig. 3. Top: Western blot showed that D-Ala2-GIP-glu-PAL inhibited the increase of α-synuclein 
expression in the SNpc induced by MPTP and probenecid. Middle: D-Ala2-GIP-glu-PAL inhibited the 
increase of α-synuclein expression in the SNpc induced by MPTP and probenecid. (A-D)-α-synuclein 
expression in SNpc were increased following treatment with MPTP and probenecid, and reduced by 
D-Ala2-GIP-glu-PAL. A: Saline; B: D-Ala2-GIP-glu-PAL; C: MPTP + probenecid; D: MPTP + 
probenecid + D-Ala2-GIP-glu-PAL. Scale bar in image C: 50μm. Graph: Quantification of average optical 
density of α-synuclein positive staining in the SNpc demonstrated that MPTP and probenecid -treated 
mouse group showed significantly higher expression of α-synuclein than saline-treated mouse group while 
D-Ala2-GIP-glu-PAL reversed the effects induced by MPTP and probenecid. Bottom: 
D-Ala2-GIP-glu-PAL inhibited the increase of α-synuclein expression in the striatum induced by MPTP 
and probenecid. (A-D)-α-synuclein expression in the striatum were increased following treatment with 
MPTP and probenecid, and reduced by D-Ala2-GIP-glu-PAL. A: Saline; B: D-Ala2-GIP-glu-PAL; C: 
MPTP + probenecid; D: MPTP + probenecid + D-Ala2-GIP-glu-PAL. Scale bar in image C: 50μm. Graph: 
Quantification of average optical density of α-synuclein positive staining in the striatum demonstrated that 
MPTP and probenecid -treated mice had a higher expression of α-synuclein than saline-treated mice while 
D-Ala2-GIP-glu-PAL reversed the effects induced by MPTP and probenecid. The values represent the 




P<0.01 compared with the MPTP 




Fig.4. Top: D-Ala2-GIP-glu-PAL reduced astrocyte activation in the SNpc induced by MPTP and 
probenecid. (A-D)-GFAP positive cell numbers were increased following treatment with MPTP 
and probenecid, and reduced by D-Ala2-GIP-glu-PAL. A: Saline; B: D-Ala2-GIP-glu-PAL; C: 
MPTP + probenecid; D: MPTP + probenecid + D-Ala2-GIP-glu-PAL. Scale bar in image C: 
200μm. A close-up of the micrograph is shown as an insert to demonstrate that the staining is 
specific for astrocytes with little background staining. Graph: Quantification of the area of GFAP 
positive stain in the SNpc demonstrated that the MPTP and probenecid -treated mouse groups had 
significantly higher expression of GFAP than saline-treated mice while D-Ala2-GIP-glu-PAL 
reversed the effects induced by MPTP and probenecid. Bottom: D-Ala2-GIP-glu-PAL reduced 
the astrocyte activation in the striatum of mice induced by MPTP and probenecid. (A-D)-GFAP 
positive cell numbers were increased following treatment with MPTP and probenecid, and 
reduced by D-Ala2-GIP-glu-PAL. A: Saline; B: D-Ala2-GIP-glu-PAL; C: MPTP + probenecid; D: 
MPTP + probenecid + D-Ala2-GIP-glu-PAL. Scale bar in image C: 200μm. Graph: Quantification 
of area of GFAP positive cell in the striatum demonstrated that MPTP and probenecid -treated 
mouse groups had significantly higher expression of GFAP than saline-treated mouse group. 
While D-Ala2-GIP-glu-PAL reversed the effects induced by MPTP and probenecid. The values 
represent the means±S.E.M. ***P<0.001 compared with the control group. 
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Fig.5. Top: D-Ala2-GIP-glu-PAL reduced microglia activation in the SNpc induced by MPTP and 
probenecid. (A-D)-IBA1 positive cell numbers were increased following treatment with MPTP 
and probenecid, and reduced by D-Ala2-GIP-glu-PAL. A: Saline; B: D-Ala2-GIP-glu-PAL; C: 
MPTP + probenecid; D: MPTP + probenecid + D-Ala2-GIP-glu-PAL. Scale bar in image C: 
200μm. A close-up of the micrograph is shown as an insert to demonstrate that the staining is 
specific for microglia. Graph: Quantification of area of IBA1 positive cell in the SNpc 
demonstrated that MPTP and probenecid -treated mouse groups had significantly higher 
expression of IBA1 than saline-treated mouse group. While D-Ala2-GIP-glu-PAL reversed the 
effects on microglia activation. Bottom: D-Ala2-GIP-glu-PAL reduced microglia activation in the 
striatum induced by MPTP and probenecid. (A-D) IBA1 positive cell numbers were increased 
following treatment with MPTP and probenecid, and reduced by D-Ala2-GIP-glu-PAL. A: Saline; 
B: D-Ala2-GIP-glu-PAL; C: MPTP + probenecid; D: MPTP + probenecid + D-Ala2-GIP-glu-PAL. 
Scale bar in image C: 200μm. Graph: Quantification of area of IBA1 positive cell in the striatum 
demonstrated that MPTP and probenecid -treated mice had significantly higher expression of 
IBA1 than saline-treated mice while D-Ala2-GIP-glu-PAL reversed the effects on microglia 
activation. The values represent the means±S.E.M. ***P<0.001 compared with the control group. 
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Fig.6. Top: D-Ala2-GIP-glu-PAL reduced lipid peroxidation in SNpc of mice induced by MPTP 
and probenecid. (A-D)-The expression of 4-HNE was increased following treatment with MPTP 
and probenecid, and reduced by D-Ala2-GIP-glu-PAL. A: Saline; B: D-Ala2-GIP-glu-PAL; C: 
MPTP + probenecid; D: MPTP + probenecid + D-Ala2-GIP-glu-PAL. Scale bar in image C: 
50μm. Graph: Quantification of average optical density of 4-HNE positive staining in the SNpc 
demonstrated that MPTP and probenecid -treated mouse groups had significantly higher 
expression of 4-HNE than saline-treated mouse group. While D-Ala2-GIP-glu-PAL reversed the 
effects induced by MPTP and probenecid. Bottom: D-Ala2-GIP-glu-PAL inhibited the lipid 
peroxidation in the striatum induced by MPTP and probenecid. (A-D) The expression of 4-HNE 
in the striatum was increased following treatment with MPTP and probenecid, and reduced by 
D-Ala2-GIP-glu-PAL. A: Saline; B: D-Ala2-GIP-glu-PAL; C: MPTP + probenecid; D: MPTP + 
probenecid + D-Ala2-GIP-glu-PAL. Scale bar in image C: 50μm. Graph: Quantification of the 
average optical density of 4-HNE positive staining in the striatum demonstrated that MPTP and 
probenecid -treated mice had significantly higher expression of 4-HNE than saline-treated mice 
while D-Ala2-GIP-glu-PAL reversed the effects induced by MPTP and probenecid. The values 
represent the means±S.E.M. ***P<0.001 compared with the control group. 
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Fig.7. D-Ala2-GIP-glu-PAL inhibited the decrease of BDNF expression in the SNpc induced by 
MPTP and probenecid treatment. The values represents the means±S.E.M. ***P<0.001 compared 
with the control group, 
#
P<0.05 compared with the MPTP and probenecid group. n=6 per group.  
 
 
